KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Intangibles (2016 - 2023)

Inovio Pharmaceuticals' Intangibles history spans 11 years, with the latest figure at $2.1 million for Q4 2022.

  • For Q4 2022, Intangibles changed N/A year-over-year to $2.1 million; the TTM value through Dec 2022 reached $2.1 million, changed N/A, while the annual FY2022 figure was $2.1 million, N/A changed from the prior year.
  • Intangibles for Q4 2022 was $2.1 million at Inovio Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Across five years, Intangibles topped out at $5.3 million in Q2 2018 and bottomed at $2.1 million in Q4 2022.
  • The 4-year median for Intangibles is $3.0 million (2021), against an average of $3.1 million.
  • The largest annual shift saw Intangibles dropped 16.15% in 2021 before it decreased 18.29% in 2022.
  • A 4-year view of Intangibles shows it stood at $5.3 million in 2018, then plummeted by 40.55% to $3.1 million in 2020, then decreased by 12.51% to $2.8 million in 2021, then dropped by 22.64% to $2.1 million in 2022.
  • Per Business Quant, the three most recent readings for INO's Intangibles are $2.1 million (Q4 2022), $2.2 million (Q3 2022), and $2.8 million (Q3 2021).